Sei Investments Co. Grows Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Sei Investments Co. boosted its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 35.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 48,180 shares of the company's stock after buying an additional 12,689 shares during the period. Sei Investments Co. owned approximately 0.13% of Tarsus Pharmaceuticals worth $2,668,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. R Squared Ltd bought a new stake in shares of Tarsus Pharmaceuticals in the 4th quarter worth about $53,000. FMR LLC grew its position in Tarsus Pharmaceuticals by 236.6% in the third quarter. FMR LLC now owns 5,032 shares of the company's stock worth $166,000 after acquiring an additional 3,537 shares in the last quarter. HighTower Advisors LLC bought a new stake in Tarsus Pharmaceuticals during the fourth quarter worth approximately $207,000. Victory Capital Management Inc. purchased a new stake in Tarsus Pharmaceuticals during the fourth quarter valued at approximately $223,000. Finally, Oppenheimer & Co. Inc. bought a new stake in shares of Tarsus Pharmaceuticals in the 4th quarter valued at approximately $227,000. Hedge funds and other institutional investors own 90.01% of the company's stock.

Insider Activity

In other Tarsus Pharmaceuticals news, insider Dianne C. Whitfield sold 2,315 shares of the company's stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $46.29, for a total transaction of $107,161.35. Following the completion of the sale, the insider now owns 50,751 shares in the company, valued at $2,349,263.79. This represents a 4.36 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, General Counsel Bryan Wahl sold 3,341 shares of the stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total transaction of $154,654.89. Following the sale, the general counsel now directly owns 58,057 shares of the company's stock, valued at approximately $2,687,458.53. The trade was a 5.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 32,542 shares of company stock worth $1,581,173. Company insiders own 8.25% of the company's stock.

Remove Ads

Tarsus Pharmaceuticals Trading Up 2.8 %

Shares of NASDAQ:TARS traded up $1.24 during trading on Wednesday, reaching $45.87. 1,203,392 shares of the company were exchanged, compared to its average volume of 681,519. The business's fifty day simple moving average is $48.53 and its 200-day simple moving average is $47.04. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38. Tarsus Pharmaceuticals, Inc. has a 12-month low of $20.08 and a 12-month high of $57.28. The firm has a market capitalization of $1.76 billion, a PE ratio of -12.04 and a beta of 0.94.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($0.60) EPS for the quarter, topping the consensus estimate of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. The company had revenue of $66.41 million for the quarter, compared to the consensus estimate of $58.80 million. On average, research analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on TARS shares. Guggenheim reissued a "buy" rating and set a $78.00 target price (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a research report on Monday, February 24th. Oppenheimer raised their target price on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an "outperform" rating in a report on Wednesday, January 22nd. Jefferies Financial Group upped their price target on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the company a "buy" rating in a report on Thursday, March 6th. HC Wainwright reissued a "buy" rating and issued a $73.00 price objective on shares of Tarsus Pharmaceuticals in a research note on Wednesday, February 26th. Finally, Barclays dropped their target price on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating for the company in a research report on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $63.67.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.